New drug combo trial for tough pancreatic cancer shows early promise
NCT ID NCT03825289
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a combination of two drugs, trametinib and hydroxychloroquine, in 25 adults with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and understand side effects. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Home monitoring may keep cancer patients out of the ER
- Nutrition check may boost quality of life in pancreatic cancer
- Experimental combo targets Hard-to-Treat GI cancers
- New drug cocktail targets cancers missing key gene
- Experimental drug combo targets Hard-to-Treat pancreatic cancer